Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Surmodics Inc (SRDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 653,300
  • Shares Outstanding, K 13,484
  • Annual Sales, $ 81,340 K
  • Annual Income, $ -4,460 K
  • 36-Month Beta 1.15
  • Price/Sales 8.28
  • Price/Cash Flow 50.12
  • Price/Book 6.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -110.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.70 +8.39%
on 12/27/18
54.56 -11.20%
on 12/18/18
-5.37 (-9.98%)
since 12/17/18
3-Month
44.70 +8.39%
on 12/27/18
68.84 -29.62%
on 11/08/18
-17.60 (-26.65%)
since 10/17/18
52-Week
25.00 +93.80%
on 02/09/18
82.35 -41.17%
on 09/04/18
+19.15 (+65.36%)
since 01/17/18

Most Recent Stories

More News
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio

The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.

SRDX : 48.45 (-3.02%)
ATHN : 133.59 (+0.05%)
VEEV : 103.45 (+1.75%)
IART : 46.36 (+0.54%)
Here's Why You Should Invest in Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.

SRDX : 48.45 (-3.02%)
VEEV : 103.45 (+1.75%)
PEN : 138.44 (+0.85%)
OPK : 3.72 (-0.27%)
Medical Products Industry Gathering Steam: 3 Stocks to Buy

The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.

MGNX : 12.54 (-2.26%)
SRDX : 48.45 (-3.02%)
BLFS : 12.64 (-0.94%)
Surmodics Sees Hammer Chart Pattern: Time to Buy?

Surmodics, Inc. (SRDX) has been struggling lately, but the selling pressure may be coming to an end soon.

SRDX : 48.45 (-3.02%)
Here's Why You Should Invest in Veeva Systems (VEEV) Now

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

SRDX : 48.45 (-3.02%)
VEEV : 103.45 (+1.75%)
PEN : 138.44 (+0.85%)
OPK : 3.72 (-0.27%)
Hill-Rom-Microsoft Tie-Up to Widen Digital Solutions Suite

Hill-Rom (HRC) progresses with efforts to gain traction in the digital health space.

MSFT : 106.12 (+0.70%)
SRDX : 48.45 (-3.02%)
VEEV : 103.45 (+1.75%)
HRC : 96.30 (+0.85%)
Integra (IART) Rises 5% on Robust Preliminary Q4 Results

Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.

SRDX : 48.45 (-3.02%)
ATHN : 133.59 (+0.05%)
VEEV : 103.45 (+1.75%)
IART : 46.36 (+0.54%)
Boston Scientific Gains on Impressive Preliminary Q4 Results

Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.

SRDX : 48.45 (-3.02%)
BSX : 36.81 (+0.52%)
ATHN : 133.59 (+0.05%)
VEEV : 103.45 (+1.75%)
ResMed Announces Complete Mobi Launch in US Markets for COPD

ResMed (RMD) progresses with efforts to boost Respiratory Care suite.

SRDX : 48.45 (-3.02%)
ATHN : 133.59 (+0.05%)
VEEV : 103.45 (+1.75%)
RMD : 117.41 (+0.44%)
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

SRDX : 48.45 (-3.02%)
ATHN : 133.59 (+0.05%)
VEEV : 103.45 (+1.75%)
QGEN : 36.64 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SRDX with:

Business Summary

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring...

See More

Key Turning Points

2nd Resistance Point 51.11
1st Resistance Point 49.78
Last Price 48.45
1st Support Level 47.61
2nd Support Level 46.76

See More

52-Week High 82.35
Fibonacci 61.8% 60.44
Fibonacci 50% 53.67
Last Price 48.45
Fibonacci 38.2% 46.91
52-Week Low 25.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar